Lung

Question 1

extensive stage small cell lung cancer who showed good response or stable disease after treatment with first-line chemotherapy,

Answer 1

Consolidation radiation!

Question 2

never smoker” refers to individuals

Answer 2

who have smoked fewer than 100 cigarettes in their lifetime.

Question 3

metastatic thymic carcinoma treatment

Answer 3

carboplatin and paclitaxel is recommended. This combination has the highest response rate in clinical trials in this disease. Sunitinib and everolimus are second-line treatment options for thymic carcinoma with lower response rates.

Question 4

first line chemo for SCLC

Answer 4

In Japan, platinum/irinotecan (PI) is the standard therapy for extensive-stage small cell lung cancer (ES-SCLC) based on a phase II and phase III trials.

Platinum/etoposide for 4 to 6 cycles is a commonly prescribed frontline regimen outside of Japan for ES-SCLC

Question 5

This patient has a peripheral T2a lesion (stage IB) squamous cell carcinoma and not surgical candidate?

Answer 5

While concurrent chemoradiation could be considered in this case, SBRT has emerged as the accepted standard for non-surgical patients with peripheral T1-2 node-negative lung cancers. Multiple studies have demonstrated competitive outcomes similar to those of surgery or sublobar (wedge) resections.

Question 6

ALK inhibitors

Answer 6

first line: alectinib ceritinib, crizotinib

second line: alectinib, ceritinib, brigatinib

Question 7

Second line for SCLC

Answer 7

topotecan